These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10989121)

  • 1. What causes the build-up of ubiquitin-containing inclusions in Parkinson's disease?
    Andersen JK
    Mech Ageing Dev; 2000 Sep; 118(1-2):15-22. PubMed ID: 10989121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson's disease?
    Jha N; Kumar MJ; Boonplueang R; Andersen JK
    J Neurochem; 2002 Feb; 80(4):555-61. PubMed ID: 11841562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin-proteasome system and Parkinson's diseases.
    Betarbet R; Sherer TB; Greenamyre JT
    Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione, iron and Parkinson's disease.
    Bharath S; Hsu M; Kaur D; Rajagopalan S; Andersen JK
    Biochem Pharmacol; 2002 Sep; 64(5-6):1037-48. PubMed ID: 12213603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
    Shimura H; Schlossmacher MG; Hattori N; Frosch MP; Trockenbacher A; Schneider R; Mizuno Y; Kosik KS; Selkoe DJ
    Science; 2001 Jul; 293(5528):263-9. PubMed ID: 11431533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.
    Liani E; Eyal A; Avraham E; Shemer R; Szargel R; Berg D; Bornemann A; Riess O; Ross CA; Rott R; Engelender S
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5500-5. PubMed ID: 15064394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggresome-related biogenesis of Lewy bodies.
    McNaught KS; Shashidharan P; Perl DP; Jenner P; Olanow CW
    Eur J Neurosci; 2002 Dec; 16(11):2136-48. PubMed ID: 12473081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson's disease.
    Fornai F; Lenzi P; Gesi M; Ferrucci M; Lazzeri G; Natale G; Ruggieri S; Paparelli A
    Curr Drug Targets CNS Neurol Disord; 2003 Jun; 2(3):149-52. PubMed ID: 12769795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitination of alpha-synuclein and autophagy in Parkinson's disease.
    Engelender S
    Autophagy; 2008 Apr; 4(3):372-4. PubMed ID: 18216494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of the ubiquitin-proteasome system in Parkinson's disease.
    McNaught KS; Olanow CW; Halliwell B; Isacson O; Jenner P
    Nat Rev Neurosci; 2001 Aug; 2(8):589-94. PubMed ID: 11484002
    [No Abstract]   [Full Text] [Related]  

  • 11. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
    Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
    J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic approach to studying Parkinson's disease.
    Zhang J; Goodlett DR
    Mol Neurobiol; 2004 Jun; 29(3):271-88. PubMed ID: 15181239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
    Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
    J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies.
    Trimmer PA; Borland MK; Keeney PM; Bennett JP; Parker WD
    J Neurochem; 2004 Feb; 88(4):800-12. PubMed ID: 14756800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lewy-body formation is an aggresome-related process: a hypothesis.
    Olanow CW; Perl DP; DeMartino GN; McNaught KS
    Lancet Neurol; 2004 Aug; 3(8):496-503. PubMed ID: 15261611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease, proteins, and prions: milestones.
    Olanow CW; McNaught K
    Mov Disord; 2011 May; 26(6):1056-71. PubMed ID: 21626551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease.
    Chung KK; Zhang Y; Lim KL; Tanaka Y; Huang H; Gao J; Ross CA; Dawson VL; Dawson TM
    Nat Med; 2001 Oct; 7(10):1144-50. PubMed ID: 11590439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson's disease.
    Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):271-82. PubMed ID: 15580550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 and Bax proteins in Lewy bodies from patients with Parkinson's disease and Diffuse Lewy body disease.
    Tortosa A; López E; Ferrer I
    Neurosci Lett; 1997 Nov; 238(1-2):78-80. PubMed ID: 9464659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dorfin localizes to the ubiquitylated inclusions in Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and amyotrophic lateral sclerosis.
    Hishikawa N; Niwa J; Doyu M; Ito T; Ishigaki S; Hashizume Y; Sobue G
    Am J Pathol; 2003 Aug; 163(2):609-19. PubMed ID: 12875980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.